These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 36124696)

  • 21. Nirmatrelvir Plus Ritonavir: First Approval.
    Lamb YN
    Drugs; 2022 Apr; 82(5):585-591. PubMed ID: 35305258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12-17 years following SARS-CoV-2 Omicron infection: A target trial emulation.
    Wong CKH; Lau KTK; Au ICH; Chan SHS; Lau EHY; Cowling BJ; Leung GM
    Nat Commun; 2024 Jun; 15(1):4917. PubMed ID: 38851796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19).
    Li H; Gao M; You H; Zhang P; Pan Y; Li N; Qin L; Wang H; Li D; Li Y; Qiao H; Gu L; Xu S; Guo W; Wang N; Liu C; Gao P; Niu J; Cao J; Zheng Y
    Clin Infect Dis; 2023 Feb; 76(3):e148-e154. PubMed ID: 35870128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nirmatrelvir and ritonavir combination against COVID-19 caused by omicron BA.2.2 in the elderly: A single-center large observational study.
    Chen C; Li R; Xing S; Cao L; Qu Y; Lv Q; Li X; Chen Z
    Immun Inflamm Dis; 2024 Apr; 12(4):e1232. PubMed ID: 38578027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-Term Effectiveness of Oral Nirmatrelvir/Ritonavir Against the SARS-CoV-2 Omicron Variant and Culture-Positive Viral Shedding.
    Lee E; Park S; Choi JP; Kim MK; Yang E; Ham SY; Lee S; Lee B; Yang JS; Park BK; Kim DS; Lee SY; Lee JY; Jang HC; Jeon J; Park SW
    J Korean Med Sci; 2023 Feb; 38(8):e59. PubMed ID: 36852855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
    Cao Z; Gao W; Bao H; Feng H; Mei S; Chen P; Gao Y; Cui Z; Zhang Q; Meng X; Gui H; Wang W; Jiang Y; Song Z; Shi Y; Sun J; Zhang Y; Xie Q; Xu Y; Ning G; Gao Y; Zhao R
    N Engl J Med; 2023 Feb; 388(5):406-417. PubMed ID: 36577095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans.
    Eng H; Dantonio AL; Kadar EP; Obach RS; Di L; Lin J; Patel NC; Boras B; Walker GS; Novak JJ; Kimoto E; Singh RSP; Kalgutkar AS
    Drug Metab Dispos; 2022 May; 50(5):576-590. PubMed ID: 35153195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Antiseizure Medications: Implications for the Management of COVID-19 in Patients with Epilepsy.
    Wanounou M; Caraco Y; Levy RH; Bialer M; Perucca E
    Clin Pharmacokinet; 2022 Sep; 61(9):1219-1236. PubMed ID: 35895276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study.
    Spiliopoulou V; Ntanasis-Stathopoulos I; Malandrakis P; Gavriatopoulou M; Theodorakakou F; Fotiou D; Migkou M; Roussou M; Eleutherakis-Papaiakovou E; Kastritis E; Dimopoulos MA; Terpos E
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis.
    Lingscheid T; Kinzig M; Krüger A; Müller N; Bölke G; Tober-Lau P; Münn F; Kriedemann H; Witzenrath M; Sander LE; Sörgel F; Kurth F
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0122922. PubMed ID: 36286542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
    Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
    BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation.
    Yan L; Bui D; Li Y; Rajeevan N; Rowneki M; Berry K; Argraves S; Huang Y; Hynes DM; Cunningham F; Huang GD; Aslan M; Ioannou GN; Bajema KL
    Clin Infect Dis; 2024 Sep; 79(3):643-651. PubMed ID: 38864601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ritonavir-boosted Nirmatrelvir and COVID-19 outcomes in the age of Omicron variant.
    Imran L; Zubair R; Mughal S; Shakeel R
    Ann Med Surg (Lond); 2023 Feb; 85(2):313-315. PubMed ID: 36845759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralizing Antibody Responses After Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 and BA.2.12.1 Infection Do Not Neutralize BA.4 and BA.5 and Can Be Blunted by Nirmatrelvir/Ritonavir Treatment.
    Carlin AF; Clark AE; Garretson AF; Bray W; Porrachia M; Santos AT; Rana TM; Chaillon A; Smith DM
    Open Forum Infect Dis; 2023 Apr; 10(4):ofad154. PubMed ID: 37096144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population-based evaluation of the effectiveness of nirmatrelvir-ritonavir for reducing hospital admissions and mortality from COVID-19.
    Schwartz KL; Wang J; Tadrous M; Langford BJ; Daneman N; Leung V; Gomes T; Friedman L; Daley P; Brown KA
    CMAJ; 2023 Feb; 195(6):E220-E226. PubMed ID: 36781188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy.
    Ciccimarra F; Luxi N; Bellitto C; L' Abbate L; De Nardo P; Savoldi A; Yeomans A; Molokhia M; Tacconelli E; Trifirò G
    BioDrugs; 2023 Sep; 37(5):675-684. PubMed ID: 37148526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data.
    Petrakis V; Rafailidis P; Trypsianis G; Papazoglou D; Panagopoulos P
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
    Sutanto ST; Sinto R; Pasaribu A; Shakinah S
    Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic Activity of Remdesivir-Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report.
    Gidari A; Sabbatini S; Schiaroli E; Bastianelli S; Pierucci S; Busti C; Saraca LM; Capogrossi L; Pasticci MB; Francisci D
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study.
    Han X; Gao D; Li C; Yuan X; Cui J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Zhao D; Zhang X; Han X; Wang B; Zhang T; Xie W; Xie L
    BMC Infect Dis; 2024 Jan; 24(1):57. PubMed ID: 38191304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.